Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals to Present at EORTC-NCI-AACR

Astex Pharmaceuticals to Present at EORTC-NCI-AACR